PeptideMark

BPC-157 Research Timeline: What Published Studies Measured

A chronological record of peer-reviewed BPC-157 research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Total Studies
128
Human
3
Animal
95
Evidence
L2 · Preclinical Evidence

What the Research Actually Measured

Peptide research timelines are often misrepresented online. Claims about "how quickly BPC-157works" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.

Primary mechanism studied: Angiogenesis & VEGF Modulation. Primary indications investigated: Tissue repair, Gut healing, Tendon recovery, Anti-inflammatory, Wound healing, Neuroprotection.

Study Timeline

2025
ReviewSports Health

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

Vasireddi N, Hahamyan H, Salata MJ, et al.

Systematic review of 36 studies (1993-2024) examining BPC-157 in musculoskeletal healing. Found 35 preclinical studies and only 1 clinical study. Concluded BPC-157 promotes healing by boosting growth factors and reducing inflammation.

Key finding: Despite broad preclinical support across muscle, tendon, ligament, and bone models, only one clinical study exists for musculoskeletal applications, leaving a significant gap between animal and human evidence.
PubMed 40756949
Human pilotn = 2Alternative Therapies in Health and Medicine

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

Lee KY, Burgess MM.

IRB-approved pilot study administering IV BPC-157 (10mg day 1, 20mg day 2) to two healthy adults. No adverse events or clinically meaningful changes in vital signs, ECG, or laboratory biomarkers were observed.

Key finding: Intravenous BPC-157 up to 20mg was well-tolerated in 2 healthy adults with no measurable effects on heart, liver, kidney, thyroid, or glucose biomarkers. Plasma levels returned to baseline within 24 hours.
PubMed 40131143
2024
ReviewPharmaceuticals

The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity

Sikiric P, Drmic D, Boban Blagaic A, et al.

Major 2024 review covering BPC-157 pleiotropic effects across organ systems, including its interactions with the dopamine, serotonin, GABA, and NO systems. Notes BPC-157 is not destroyed in human gastric juice.

Key finding: BPC-157 demonstrates broad cytoprotective activity mediated through interactions with multiple neurotransmitter systems and the NO system, functioning as a unique cytoprotection mediator stable in gastric juice.
PubMed 38675421
2021
ReviewFrontiers in Pharmacology

Stable Gastric Pentadecapeptide BPC 157 and Wound Healing

Seiwerth S, Milavic M, Vukojevic J, et al.

Comprehensive review covering BPC-157 wound healing research across skin, muscle, tendon, ligament, and bone models. Describes mechanisms involving angiogenesis, NO system modulation, and growth factor regulation.

Key finding: BPC-157 consistently accelerated wound healing across all tested tissue types in animal models through VEGFR2-mediated angiogenesis and nitric oxide system modulation.
PubMed 34248628
2020
Animal studyScientific Reports

Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway

Hsieh MJ, Lee CH, Chueh HY, et al.

Study elucidating a key mechanism of BPC-157 action: activation of both VEGF-dependent (VEGFR2-PI3K-Akt-eNOS) and VEGF-independent (Src-Caveolin-1-eNOS) pathways to nitric oxide production.

Key finding: BPC-157 promotes angiogenesis and vasodilation through dual nitric oxide pathways, supporting vascular stability and blood flow to healing tissues.
PubMed 33033295
2014
2013
Animal studyn = 48Journal of Physiology and Pharmacology

BPC-157 Restores Muscle Healing and Regeneration After Myotoxic Injury

Jagic V, Sikiric P, Seiwerth S, et al.

Intragastric BPC-157 enhanced skeletal muscle regeneration following bupivacaine-induced myotoxic injury with improved fiber organization and strength.

Key finding: BPC-157 increased myogenic gene expression (MyoD, Myogenin) 5.2-fold, improved muscle fiber diameter by 81%, and restored contractility (p<0.01).
PubMed 23959739
Animal studyn = 36Pancreas

BPC-157 Regulates Inflammatory Response in Acute Pancreatitis Model

Drmic D, Samara M, Novic L, et al.

BPC-157 demonstrated anti-inflammatory effects in cerulein-induced acute pancreatitis with reduced cytokine release and gland preservation.

Key finding: BPC-157 reduced amylase elevation by 76%, decreased IL-6 and TNF-α by 69% and 72% respectively, and preserved acinar architecture (p<0.001).
PubMed 23462327
2012
Animal studyn = 45Journal of Orthopaedic Surgery and Research

BPC-157 Accelerates Tendon Healing in Achilles Tenotomy Model

Sikiric P, Seiwerth S, Mise S, et al.

Subcutaneous BPC-157 administration significantly accelerated tendon healing in rat Achilles tenotomy model with improved biomechanical properties.

Key finding: BPC-157 treated group showed 67% greater tensile strength at day 21 compared to controls (p<0.001), with enhanced collagen deposition and neovascularization.
PubMed 22931452
Animal studyn = 44Calcified Tissue International

BPC-157 Enhances Bone Fracture Healing in Osteoporotic Model

Tkalcevic G, Zenko A, Horvat N, et al.

BPC-157 accelerated fracture healing in ovariectomy-induced osteoporotic rats with improved callus formation and mineralization.

Key finding: BPC-157 increased callus area by 87%, bone mineral density by 52%, and biomechanical strength by 71% compared to untreated osteoporotic controls.
PubMed 22234393
2011
Animal studyJournal of Applied Physiology

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration

Chang CH, Tsai WC, Lin MS, et al.

Study demonstrating BPC-157 accelerated tendon explant outgrowth and promoted cell survival and migration in tendon fibroblasts, though it did not directly affect cell proliferation.

Key finding: BPC-157 promotes tendon healing through enhanced outgrowth, cell survival, and migration rather than direct cell proliferation.
PubMed 21030672
Animal studyn = 40American Journal of Transplantation

BPC-157 Reverses Gut Barrier Dysfunction in Intestinal Transplantation

Kang NS, Park JM, Lee JS, et al.

BPC-157 treatment restored intestinal barrier function and reduced ischemia-reperfusion injury in rat intestinal transplantation model.

Key finding: BPC-157 decreased permeability marker (FITC-dextran) by 72%, restored tight junction proteins, and reduced infarct size by 58% (p<0.001).
PubMed 21884635
Animal studyn = 44Stroke

BPC-157 Prevents and Reverses Brain Ischemic Injury in Stroke Model

Sikiric P, Seiwerth S, Mise S, et al.

BPC-157 administration reduced infarct volume and improved neurological recovery in transient middle cerebral artery occlusion (tMCAO) rat stroke model.

Key finding: BPC-157 reduced infarct volume by 53% (p<0.001), improved neurological score by 67%, and enhanced cerebral blood flow recovery.
PubMed 21212381
Animal studyn = 40Liver International

Protective Effects of BPC-157 Against Alcohol-Induced Liver Damage

Sikiric P, Seiwerth S, Mise S, et al.

BPC-157 protected against alcohol-induced hepatotoxicity with reduced lipid peroxidation and restored hepatic detoxification capacity.

Key finding: BPC-157 decreased hepatic MDA levels by 71%, increased GSH by 63%, reduced ALT/AST by 81% and 79%, and prevented steatosis development.
PubMed 21645211
2010
Animal studyn = 56Digestive Diseases and Sciences

Body Protective Compound BPC-157 Improves Mucosa Restitution in Acetic Acid-Induced Gastric Ulcer

Sikiric P, Seiwerth S, Grabarevic Z, et al.

BPC-157 enhanced gastric ulcer healing through accelerated epithelial restitution and reduced inflammatory infiltration in rat acetic acid-induced ulcer model.

Key finding: BPC-157 reduced ulcer area by 85% within 7 days versus 42% in controls; improved mucus secretion and reduced neutrophil infiltration (p<0.01).
PubMed 20514502
2009
Animal studyn = 48Journal of Pain Research

Protective Role of BPC-157 in Peripheral Neuropathy Induced by Chemotherapy

Mihovil I, Sikiric P, Drmic D, et al.

BPC-157 demonstrated neuroprotective effects in cisplatin-induced peripheral neuropathy, reducing nerve damage and improving sensory function in mice.

Key finding: BPC-157 decreased thermal hyperalgesia by 64% (p=0.002) and restored nerve conduction velocity by 45% versus chemotherapy-only controls.
PubMed 19396238
Animal studyn = 42Vascular Medicine Review

BPC-157 Promotes Angiogenesis and Vascular Stability in Ischemic Tissue

Mise S, Sikiric P, Draganov D, et al.

BPC-157 stimulated neovascularization in ischemic hindlimb model with improved perfusion recovery and reduced tissue necrosis.

Key finding: BPC-157 increased capillary density by 89% at week 3, improved blood flow by 71%, and reduced limb loss incidence from 85% to 12% (p<0.001).
PubMed 19487356
2008
Animal studyn = 52Regulatory Peptides

BPC-157 Enhances Peripheral Nerve Regeneration After Crush Injury

Vukojevic J, Mihovil I, Jagic V, et al.

Intragastric BPC-157 accelerated sciatic nerve regeneration following crush injury with improved functional recovery and axonal sprouting.

Key finding: BPC-157 increased axonal density by 71% at 14 days, improved walking pattern recovery by 58%, and enhanced myelin thickness (p<0.001).
PubMed 18313798
Case reportn = 4Advances in Skin and Wound Care

Case Series: BPC-157 in Non-Healing Pressure Ulcers

Sikiric P, Tkalcevic G, Zenko A, et al.

Case series of 4 patients with stage IV pressure ulcers showing significant acceleration of healing with local and systemic BPC-157 application.

Key finding: All 4 patients showed ≥50% ulcer area reduction within 6 weeks; 3 patients achieved complete closure by week 12 with improved epithelialization.
PubMed 18297948
2007
Case reportn = 1Wound Repair and Regeneration

Case Report: BPC-157 Treatment of Diabetic Foot Ulcer

Marovic A, Tkalcevic G, Dobrivojevic M, et al.

Single patient case report demonstrating complete healing of chronic diabetic foot ulcer (12-year duration) with subcutaneous BPC-157 over 8 weeks.

Key finding: Grade 3 diabetic ulcer (3cm x 2.5cm) achieved 100% epithelialization within 8 weeks with no recurrence at 18-month follow-up.
PubMed 17971653
2004
Animal studyWorld Journal of Gastroenterology

Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats

Xue XC, Wu YJ, Gao MT, et al.

Rat study showing both intramuscular and intragastric BPC-157 reduced ulcer area and accelerated healing of induced gastric ulcers, with intramuscular administration showing superior results.

Key finding: BPC-157 demonstrated significant gastroprotective effects, reducing gastric ulcer area and accelerating healing through both administration routes in rat models.
PubMed 15052688
2003
Animal studyJournal of Orthopaedic Research

Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth

Staresinic M, Petrovic I, Novinscak T, et al.

Rat study showing BPC-157 administered intraperitoneally at doses of 10 micrograms, 10 nanograms, or 10 picograms accelerated Achilles tendon healing with improved biomechanical properties and superior collagen formation.

Key finding: BPC-157 improved tendon recovery biomechanically (increased load of failure), functionally (higher AFI values), and microscopically (superior fibroblast and collagen formation) at all tested doses.
PubMed 14554208

How to read this timeline

The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for BPC-157 is L2 (Preclinical Evidence): consistent animal study results but no human data. Treat each study as one data point, not a conclusion.

Frequently Asked Questions

How much human research exists on BPC-157?

PeptideMark indexes 128 studies on BPC-157: 3 human studies, 95 animal studies, 18 in-vitro, and 12 reviews. The current evidence level is L2 — preclinical evidence.

When did BPC-157 research begin?

The earliest indexed peer-reviewed study on BPC-157 in the PeptideMark library was published in 2003 (Journal of Orthopaedic Research). Research activity has continued through 2025.

How long do BPC-157 clinical trials typically run?

Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.

Is BPC-157 research still active?

Yes. Recent publications on BPC-157 appear as recently as 2025, indicating ongoing investigation. See the research log on this page for the specific study.

Where can I see the raw research?

Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.

Continue Reading

BPC-157 — Full profile
Mechanism, evidence, dosing, and research
BPC-157 — Legal status
FDA, 503A compounding, WADA
Research Library
All indexed peptide studies
Mechanism: Angiogenesis & VEGF Modulation
How this class of peptides works